Clinical Trial Update: Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial is evaluating venetoclax to prevent differentiation syndrome in patients with acute promyelocytic leukemia, with enrollment by …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• Venetoclax (venetoclax)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Promyelocytic Leukemia | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION